Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $89.00

Rapport Therapeutics (NASDAQ:RAPP) had its target price hoisted by BTIG Research from $75.00 to $89.00 in a research report report published on Tuesday morning, Marketbeat reports. They currently have a buy rating on the stock.

A number of other equities research analysts also recently commented on RAPP. UBS Group started coverage on Rapport Therapeutics in a report on Thursday, October 15th. They issued a “buy” rating and a $71.00 price objective for the company. Leerink Partners initiated coverage on Rapport Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $52.00 target price on the stock. William Blair assumed coverage on Rapport Therapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating for the company. Wall Street Zen lowered Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, HC Wainwright upped their price target on Rapport Therapeutics from $40.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $68.36.

Rapport Therapeutics Price Performance

RAPP stock opened at $26.53 on Tuesday. The business’s fifty day moving average is $39.44 and its 200-day moving average is $39.02. Rapport Therapeutics has a twelve month low of $23.75 and a twelve month high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, equities research analysts forecast that Rapport Therapeutics will post -4.09 EPS for the current year.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, Director Steven M. Paul bought 35,714 shares of the firm’s stock in a transaction on Thursday, October 22nd. The stock was purchased at an average cost of $27.28 per share, with a total value of $974,277.92. Following the completion of the purchase, the director owned 77,380 shares in the company, valued at approximately $2,110,926.40. The trade was a 85.71% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Abraham Ceesay sold 28,958 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total value of $1,390,273.58. Following the completion of the sale, the chief executive officer owned 486,108 shares of the company’s stock, valued at $23,338,045.08. This trade represents a 5.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders acquired 58,094 shares of company stock valued at $1,566,358 and sold 97,976 shares valued at $4,420,349. Insiders own 12.48% of the company’s stock.

Hedge Funds Weigh In On Rapport Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV bought a new stake in Rapport Therapeutics during the 1st quarter worth approximately $30,000. Sterling Capital Management LLC raised its holdings in Rapport Therapeutics by 597.9% during the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after buying an additional 843 shares during the period. State of Wyoming acquired a new stake in Rapport Therapeutics during the 2nd quarter worth approximately $65,000. Meeder Asset Management Inc. bought a new position in Rapport Therapeutics in the second quarter valued at approximately $116,000. Finally, AlphaCentric Advisors LLC lifted its stake in Rapport Therapeutics by 6.8% in the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock valued at $201,000 after buying an additional 408 shares in the last quarter.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The candidate produced statistically significant placebo-adjusted improvements in YMRS and CGI-BP mania-severity scores. Rapport plans to begin Phase 3 trials, potentially expanding RAP-219’s commercial opportunity beyond epilepsy. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts increased or maintained bullish valuations. JonesTrading raised its target to $82, while BTIG reportedly lifted its target to $89. Raymond James raised its target to $86, and HC Wainwright reaffirmed its Buy rating. The consensus target is approximately $68.36, well above recent trading levels. BTIG price target increase
• Positive Sentiment: Company insiders made substantial open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while four directors purchased an additional 52,594 shares. The combined purchases were worth approximately $1.57 million and may signal management confidence following the clinical update. SEC insider filings
• Neutral Sentiment: RAP-219’s move toward Phase 3 is an important milestone, but investors still face clinical, regulatory, financing, and commercialization uncertainty typical of a clinical-stage biotechnology company.
• Negative Sentiment: The clinical results may have been less decisive than some investors expected. Reports indicated that portions of the data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport also remains unprofitable; its latest quarterly loss exceeded analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. Rapport bipolar data report

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.